Control of Neurona l E xcita bilit y
The major cannabinoid receptor in the central nervous system is cannabinoid receptor 1 (CB 1 R), a presynaptic, G-protein-coupled receptor that activates voltage-gated calcium channels and enhances potassium-channel conduction in presynaptic terminals. The cloning of CB 1 R, the confirmation that Δ 9 -THC binds CB 1 R, and the discovery of two endogenous ligands -2-arachidonoylglycerol (2-AG) and anandamide -that bind CB 1 R 7 has stimulated investigations intended to elucidate the role of the endocannabinoids both in normal brain function and in disease states. CB 1 R is activated by the activity-dependent synthesis of 2-AG and is involved in the retrograde control of synaptic transmission. Anandamide can also affect excitability in neuronal networks by activating the transient receptor potential (TRP) cation channel, subfamily V, member 1. 11 As modulators of neuronal excitability, endogenous cannabinoids are well poised to affect the initiation, propagation, and spread of seizures.
Preliminary studies have identified defects in The exact targets that mediate the antiseizure effects of cannabinoids are unknown. Several cannabinoids are known to bind to multiple targets in the central nervous system and exert effects at nanomolar or low micromolar concentrations. These targets include transient receptor potential cation channel, subfamily V, members 1, 2, and 3 (TRPV1-3), glycine receptor α (α 3 GlyR), peroxisome proliferator-activated receptor gamma (PPAR-γ), calcium-gated ion channel (Ca v 3 ion channel), and diacylglycerol lipase α (DAGL-α). There are conflicting results from multiple studies on the effects of Δ 9 -tetrahydrocannabinol on G-protein-coupled receptor (GPR) 55. CB 1 R and CB 2 R denote cannabinoid receptor types 1 and 2, 5-HT the serotonin receptors 5-hydroxytryptophan type 1A and 3A, TRPA transient receptor potential cation channel, subfamily A, and TRPM transient receptor potential cation channel, subfamily M. Adapted from Cascio and Pertwee 9 and Pertwee and Cascio. the endocannabinoid system in persons with epilepsy. In one study, patients with newly diagnosed temporal-lobe epilepsy had significantly lower levels of anandamide in cerebrospinal fluid than healthy controls. 12 In another study, tissue resected from patients undergoing surgery for epilepsy had lower levels of CB 1 R messenger RNA, particularly in the glutamatergic terminals in the dentate gyrus, than did specimens obtained post mortem from persons without epilepsy. There was also reduced expression of diacylglycerol lipase α (DAGL-α), the enzyme responsible for the "on-demand" synthesis of 2-AG in postsynaptic neurons. 13 These studies support the suggestion that the endocannabinoid system plays a role in the inhibition of seizures in humans with epilepsy.
The endocannabinoid system is strongly activated by seizures, and the upregulation of CB 1 R activity has antiseizure effects. In mice, hippocampal anandamide levels rise after seizures induced by the intraperitoneal injection of kainic acid.
14 In cultures of neurons from the hippocampus, CB 1 R antagonists induce prolonged, seizurelike discharges, 15 whereas CB 1 R agonists eliminate these discharges. 16 Conditional knockout mice that lack pyramidal-cell CB 1 R in their forebrain have more severe and prolonged seizures than wild-type mice in response to kainic acid 14, 17 ; in contrast, viral-vector-mediated overexpression of CB 1 R in hippocampal pyramidal cells is protective. 18 Reducing the metabolic degradation of endocannabinoids ameliorates experimentally induced seizures. 19 
Pr eclinic a l E v idence of A ntiseizur e Effec ts
The activation of CB 1 R receptors with the use of Δ 9 -THC or synthetic agonists in experimentally induced seizures has been studied in various animal models (see Hill et al. for a summary 20 ). In most studies, CB 1 R agonists reduced seizures, but in others no effect was observed, and in four studies CB 1 R activation was associated with convulsant effects at some doses. CB 1 R antagonists reduced the threshold for seizure in some studies in animals, 21 a finding that further supports the possibility that CB 1 R activation has anticonvulsant effects.
Other plant cannabinoids have also been studied in animal models of seizures and epilepsy. Cannabidiol, the most abundant nonpsychoactive cannabinoid, has shown antiseizure effects in several in vivo and in vitro models of epilepsy. 22 Unlike Δ 9 -THC, cannabidiol does not exert its main neural effects through the activation of CB 1 R. At high levels, cannabidiol may function as an indirect CB 1 R antagonist. 23 Cannabidiol alters neuronal excitability by other means. These include binding to members of the TRP family of cation channels at low levels, 24 which antagonizes the G-protein-coupled receptor 55, leading to decreased presynaptic release of glutamate 25 ; activating 5-hydroxytryptophan 1A receptors 26 ; and inhibiting adenosine reuptake through multiple mechanisms. 27 In addition, cannabidiol may exert antioxidant and antiinflammatory effects. 28 Cannabidiol's lack of psychoactive effects and the preclinical evidence of antiseizure effects has generated interest in its potential as an antiseizure drug in humans.
Cannabidivarin, the propyl variant of cannabidiol, has also shown antiseizure effects in both in vitro and in vivo models. 29 Like cannabidiol, cannabidivarin has antiseizure effects that are independent of the endocannabinoid system and may function by means of its influence on TRP channels or by lowering 2-AG synthesis through the inhibition of DAGL-α. 30 Little is known about the antiseizure effects of other phytocannabinoids. Cannabinol and Δ 9 -THCV, the propyl variant of Δ 9 -THC, have been shown to have anticonvulsant effects in a few small studies. 20 
Ev idence of A ntiseizur e Effec ts in Hum a ns
Despite the preclinical data and anecdotal reports on the efficacy of cannabis in the treatment of epilepsy that include reports from epileptologists, 31 -34 a recent Cochrane review concluded that "no reliable conclusions can be drawn at present regarding the efficacy of cannabinoids as a treatment for epilepsy" 35 owing to the lack of adequate data from randomized, controlled trials of Δ 9 -THC, cannabidiol, or any other cannabinoid (Table 1 ). This assessment was confirmed in a recent systematic review by the American Academy of Neurology. Several patient and caregiver surveys have examined the effects of cannabis in epilepsy. In one survey, 28 of 136 patients in an epilepsy center that provided tertiary care reported cannabis use. Most of these patients associated use with a reduction in seizure frequency and severity. 45 A 2013 survey of caregivers of 19 children with severe epilepsy who were receiving cannabidiol-enriched cannabis extracts indicated that 2 of the children had become seizure-free and 8 others had a reduction in the frequency of seizures of 80% after taking the extract. 42 In a 2015 survey of 75 parents whose children were treated with oral cannabis extracts in Colorado, the parents reported that one third of the children had a reduction in seizures of more than 50%. 34 However, electroencephalograms were obtained for 8 of these children before and after the administration of cannabis, and none showed improvement in background activity.
Case reports support the antiseizure effects of cannabis in patients with epilepsy 6,32-34, 49 and show exacerbation of seizures after abrupt discontinuation. 50 However, in a survey conducted in Germany among adults with epilepsy who used cannabis, the substance had no apparent effect on seizure control, 46 and some case reports have shown an exacerbation of seizures among patients who used cannabis 43,51 or a synthetic cannabinoid. 52 Few prospective therapeutic trials have been performed that involve the isolated use of cannabinoids to treat epilepsy. A study conducted in 1949 indicated that two of five institutionalized children with refractory epilepsy achieved seizure control after receiving treatment with a Δ 9 -THC analogue. 36 To our knowledge, only four placebo-controlled studies of the use of cannabinoids for the treatment of epilepsy have been performed (reviewed in Gloss and Vickrey 35 ). All the studies were considerably underpowered and had methodologic problems, including the lack of blinding. Two studies showed a reduction in the number of seizures in patients treated with cannabidiol, whereas the other two studies showed no effect.
Since 2013, a consortium of 10 epilepsy centers has been collecting prospective data on children and young adults with severe epilepsy who are receiving Epidiolex, a purified cannabis extract containing 99% cannabidiol and less than 0.10% Δ 9 -THC (GW Pharmaceuticals), through an expanded-access program authorized by the Food and Drug Administration (FDA). A preliminary report from this open-label study, initiated by investigators to assess the safety and dosing of cannabidiol, noted that among 137 patients who had received at least 12 weeks of treatment, the median reduction in the number of seizures was 54%. 41 Randomized clinical trials of Epidiolex are now being conducted for the treatment of two forms of severe, childhoodonset epilepsy: Dravet's syndrome (a severe myoclonic epilepsy of infancy) (NCT02091375) and the Lennox-Gastaut syndrome (a childhood-onset, treatment-resistant epilepsy characterized by multiple types of seizures and developmental delay) (NCT02224690). Although some of the anecdotal evidence described above suggests that cannabidiol-rich treatments may ameliorate seizures in patients with these disorders, no evidence suggests that the antiseizure effects of cannabidiol are limited to the treatment of these conditions. The clinical development of synthetic forms of cannabidiol is also in progress (NCT02318563). Table 1 summarizes the current clinical evidence for the use of cannabinoid-containing compounds in the treatment of epilepsy.
Sa fe t y in Hum a ns
Much of the available data regarding the safety and side-effect profile of cannabinoids, especially with long-term use, come from studies examining the effects of recreational use.
53,54
The short-term side effects of cannabis use may include impairment of memory, judgment, and motor performance. High levels of Δ 9 -THC are associated with psychosis and an increased risk of motor-vehicle accidents. With long-term use there is a risk of addiction, which occurs in approximately 9% of long-term users. Other effects of long-term use include cognitive impairment, decreased motivation, and an increased risk of psychotic disorders.
Cannabis-based treatment with Δ 9 -THC may have irreversible effects on brain development. T h e ne w e ngl a nd jou r na l o f m e dicine
The endocannabinoid system undergoes development in childhood and adolescence; long-term exposure to endocannabinoids, especially Δ 9 -THC, may lead to cognitive and behavioral changes. Imaging studies of the brain reveal altered structure and function in long-term adult users, including impaired connectivity of the prefrontal cortices and precuneus 54 and decreased volume in the hippocampi and amygdalae. 55 Long-term use of cannabis in childhood may be associated with lower-than-expected IQ scores 56 (although socioeconomic status may be a confounding factor; see Rogeberg 57 ). It is unknown whether adverse effects on the brain are mediated solely by psychoactive cannabinoids, such as Δ 9 -THC, or whether long-term exposure to cannabidiol and cannabidivarin also have deleterious effects. Until more data become available, the neurodevelopmental risks of cannabinoid-based therapies should be weighed against the potential benefits for seizure control, since seizures also affect brain development. Notably, scientific data on the potential long-term developmental effects of FDA-approved antiseizure drugs are also limited.
Many antiseizure drugs are associated with teratogenicity and neurodevelopmental impairments in children who are exposed in utero. Little is known about the effects of fetal exposure to cannabinoids. Studies of children born to parents who are recreational cannabis users have not shown an increased risk of congenital abnormalities, but difficulties with attention, impulse control, and executive function have been reported. 58 However, potential confounding factors, such as socioeconomic status and coexisting maternal psychiatric illness, limit the extent to which these findings can be interpreted.
Data regarding the outcomes of short-term and long-term exposure to cannabinoids in recreational users are often confounded by the factors that drive a person to use cannabis. More valid data regarding the safety of short-term use comes from randomized clinical trials of cannabinoid-containing medications, including purified cannabis extracts (Cannador, Society for Clinical Research, Germany; 2:1 ratio of Δ 9 -THC and cannabidiol), 59 nabixomols (Sativex, GW Pharmaceuticals, 1:1 ratio of Δ 9 -THC and cannabidiol), 60 and the synthetic Δ 9 -THC analogues dronabinol (Marinol, Unimed Pharmaceuticals), 61 and nabilone (Cesamet, Valeant Pharmaceuticals). 62 These trials involved the systematic collection of data on safety. In a pooled analysis that included 1619 patients in short-term placebo-controlled studies who received cannabinoids for the treatment of pain and tremor and for spasticity related to multiple sclerosis, 6.9% withdrew because of adverse effects, as compared with 2.2% who withdrew in the placebo groups. 47 Adverse effects that occurred in more than one study included nausea, weakness, mood changes, psychosis, hallucinations, suicidal ideation, dizziness or lightheadedness, fatigue, and feeling of intoxication. No deaths from overdose were reported in association with cannabinoid-containing medications. In small studies of cannabidiol use in healthy volunteers and in patients with multiple disease conditions, serious side effects have been associated with either long-term or short-term administration of doses of up to 1500 mg daily. 63 In the preliminary results of an open-label study of the use of cannabidiol oral solution for severe, refractory, childhood-onset epilepsy, the most common side effects were somnolence (occurring in 21% of the participants), diarrhea (17%), fatigue (17%), and decreased appetite (16%). Increased frequency or severity of seizures, weight loss, diarrhea, pneumonia, and abnormal results on tests of liver function were less common, occurring in 1 to 7% of patients. 41 Long-term recreational use of cannabis is associated with a risk of dependence. 54 Little is known regarding the potential for the abuse of cannabinoid-based treatments when they are administered in a clinical setting. A single-dose, double-blind, crossover study involving 23 recreational cannabis users showed higher scores on scales of drug preference for dronabinol and high-dose nabiximols but not for low-dose nabiximols, 64 which suggests that there may be a potential for abuse associated with cannabinoidbased therapies, at least when the compounds used contain Δ 9 -THC or its analogues. Few data are available on the effects of other cannabinoids, although the relative absence of psychoactive effects reported for cannabidiol and cannabidivarin suggests that the potential for abuse of these compounds is low.
Some safety concerns have been raised with regard to the pharmacokinetic interactions of cannabinoids in patients with epilepsy who are long-term users. Cannabinoids can inhibit cytochrome P-450 (CYP) enzymes. Both at low micromolar concentrations and CYP3A4 at higher concentrations. 65 These enzymes help to metabolize many antiseizure drugs, 66 and inhibition can potentiate drug toxicity and efficacy. Both cannabidiol and Δ 9 -THC are metabolized through the P-450 system, especially through CYP2C9 and CYP3A4. 65 These isozymes are induced by commonly prescribed antiseizure drugs, such as carbamazepine, topiramate, and phenytoin, and are inhibited by others, such as valproate, 66 and the potential for drug-drug interactions between antiseizure drugs and cannabinoids is bidirectional. Preliminary evidence suggests that cannabidiol can raise the serum levels of the N-desmethyl metabolite of clobazam, which can have antiseizure and sedative effects. 67 As is the case with any medication, accidental ingestion of cannabis by children is a concern, and with cannabis preparations, the concern is particularly great because these preparations are not packaged in childproof containers and because some are made in formulations that may be appealing to children (gummies, brownies, or other edible forms). 68 Finally, there are safety concerns related to the preparation of cannabis for medicinal use. Although many states have approved the use of "medical" marijuana, patients or caregivers often process the plant for therapeutic use. Reliance on recipes pulled from the Internet that use butane or high-proof alcohols to extract cannabinoids from plant material has resulted in more than 30 home explosions in a 5-month period in Colorado. 69 
Issues R eleva nt t o Use in Epilepsy Tr e atment
The delay between initial reports of the antiseizure efficacy of cannabinoids in preclinical models in the 1970s and the recent start of clinical studies reflects, in part, the classification of cannabis and any product derived from it as a Schedule I drug by the Drug Enforcement Agency. Schedule I drugs are defined as having no currently accepted medical use and a high potential for abuse. 70 Synthetic cannabinoids, since they are not derived from the cannabis plant, are sometimes subject to less restrictive scheduling if clinical evidence supports medical usefulness. For instance, the synthetic Δ 9 -THC isomer dronabinol is a Schedule III medication and is often prescribed for the treatment of chronic nausea and vomiting in patients with the autoimmune deficiency syndrome. The rationale for the discrepancy between restrictions governing naturally occurring cannabinoids and synthesized cannabinoids is not clear. Cannabisbased drugs such as nabiximols (cannabidiol and Δ 9 -THC) have been approved by regulatory bodies in more than 20 countries on the basis of the results of clinical trials that have established efficacy and a favorable safety profile, including a low potential for abuse. 71 The Schedule I category limits the availability of pure cannabidiol, Δ 9 -THC, and other cannabinoids derived from cannabis while placing a high regulatory burden on investigators who want to study these agents in cell cultures, animal models, or patients. This burden includes the need to purchase and find space for expensive and heavy safes, add locks and security systems to the laboratory or clinic, and complete a long and complex process to apply for and then pass multiple inspections in order to possess these compounds. Paradoxically, as more state legislatures give the lay community access to diverse strains and preparations of cannabis and federal policy continues to limit the access of scientific and clinical investigators to compounds such as cannabidiol, a dissociation is created between an exponential rise in use and a slow rise in scientific knowledge.
Percei v ed Ther a peu tic Benefit
Another obstacle to scientific inquiry into cannabinoids for the treatment of epilepsy is the perception among many patients and caregivers that sufficient evidence of their safety and efficacy already exists. 72 The gap between patient beliefs and available scientific evidence highlights a set of factors that confound cannabinoid research and therapy, including the naturalistic fallacy (the belief that nature's products are safe), the conversion of anecdotes and strong beliefs into facts, failure to appreciate the difference between research and treatment, 73 and a desire to control one's care, including access to therapies of perceived benefit. 74 In one study of children with epilepsy in Colorado, the rate of response to therapy reported by parents who had moved their family to the state to receive cannabinoid therapy was more than twice as high as that reported by parents who were already residing in the state (47% vs. 22%). 34 This finding suggests that the stronger the belief that the drug will be beneficial and the greater the sacrifice involved to obtain the drug, the greater the reported response. In the future, randomized, controlled studies of cannabinoids will have to contend with large placebo effects that may actually prevent researchers from demonstrating the efficacy of cannabinoids over placebo. The currently planned randomized clinical trials of cannabidiol will target primarily children with severe epilepsy. Placebo response rates are high among children and adolescents with a wide variety of conditions, including pain-related disorders (e.g., migraines and gastrointestinal disorders), medical disorders (e.g., asthma), and psychiatric disorders (e.g., anxiety, major depression, obsessive-compulsive disorder, and attentiondeficit disorder). 75 The issue of high response rates to placebos in studies of children is especially relevant to epilepsy and emphasizes the importance of placebo-controlled trials. A metaanalysis showed that among patients with treatment-resistant focal epilepsy, children had more improvement with placebo than did adults (19.9% vs. 9.9%), although there was no significant difference in the response to active treatment. 76 Children with intellectual disability and severe epilepsy are especially prone to elevated response rates to placebo. For instance, in a clinical trial of clobazam in children with the Lennox-Gastaut syndrome (mean age, 12.4 years), the response rate (defined as a decline of more than 50% in the number of drop seizures [brief seizures associated with a sudden increase or decrease in muscle tone, often causing a fall if the person is standing]) in the placebo group was 31.6%, a rate similar to that in the group receiving clobazam. However, the average weekly frequency of seizures was significantly lower in the clobazam group. 
Conclusions a nd Fu t ur e Dir ec tions
Preclinical and preliminary data from studies in humans suggest that cannabidiol and Δ 9 -THC may be effective in the treatment of some patients with epilepsy. However, current data from studies in humans are extremely limited, and no conclusions can be drawn. Relaxation of the regulatory status of cannabis-derived drugs, especially those containing a high proportion of nonpsychoactive cannabinoids, for which the potential for abuse is low, could help to accelerate scientific study. Despite the power of anecdote and the approval of medical cannabis by many state legislatures, only double-blind, placebocontrolled, randomized clinical trials in which consistent preparations of one or more cannabinoids are used can provide reliable information on safety and efficacy. The use of medical cannabis for the treatment of epilepsy could go the way of vitamin and nutritional supplements, for which the science never caught up to the hype and was drowned out by unverified claims, sensational testimonials, and clever marketing. If randomized clinical trials show that specific cannabinoids are unsafe or ineffective, those preparations should not be available. If studies show that specific cannabinoids are safe and effective, those preparations should be approved and made readily available.
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